证券代码：300529 证券简称：健帆生物 公告编号：2023-095 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2023 年 6 月 19 日 召开了 2023 年第一次临时股东大会，审议通过了《关于修订＜公司章程＞的议 案》，鉴于公司回购注销 2021 年限制性股票激励计划未能解禁的第一类限制性股 票 15.60 万股，使得公司总股本相应减少 15.60 万股，公司总股本从 80771.1312 万股减少至 80755.5312 万股，公司注册资本由 80771.1312 万元减少至 80755.5312 万元。 近日，公司完成了工商登记变更及《公司章程》备案，并取得了珠海市市场 监督管理局换发的《营业执照》。具体相关信息如下： 一、基本情况 8、经营范围：许可项目：第三类医疗器械生产；第三类医疗器械经营；第 三类医疗器械租赁；第二类医疗器械生产；食品销售；第二类增值电信业务；医 疗器械互联网信息服 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2023-094 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 关于公司两项新产品取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"健帆生物"或"公司"）于近 日收到国家药品监督管理局颁发的两项《医疗器械注册证》，公司的新产品一次 性使用血液灌流器、连续性肾脏替代治疗用管路分别取得医疗器械注册证。其中， 一次性使用血液灌流器（pHA 系列）是国内首个获批的可以同时清除终末期肾 病（ESRD）患者体内蛋白结合毒素和中大分子毒素的血液灌流器产品，连续性 肾脏替代治疗用管路是临床进行连续性血液净化（CRRT）治疗中必不可少的一 次性使用医疗器械耗材。具体情况如下： | 序 | 产品名称 | 注册证 | 分类 | 注册证有 | 型号、规格 | 适用范围 | 注册人 | | --- | --- | --- | --- | --- | --- | --- | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次完成回购注销的限制性股票共计 156,000 股，占回购前健帆生物科 技集团股份有限公司（以下简称"公司"）总股本的 807,711,312 股的 0.0193%， 涉及激励对象 5 人。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司已于 2023 年 8 月 10 日办理完成上述限制性股票的回购注销手续。 证券代码：300529 证券简称：健帆生物 公告编号：2023-093 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于部分限制性股票回购注销完成暨不调整健帆转债转股 价格的公告 3、本次限制性股票回购注销完成后，公司总股本由 807,711,312 股变更为 807,555,312 股。 4、因公司本次股份变动数量占公司总股本的比例很小，经计算，本次限制 性股票回购注销完成后，"健帆转债"的转股价格不变，仍为 61.72 元/股。 一、本激励计划简述 1、2021 年 2 月 4 日公司召开第四届董事会第十次会议，审议通过了《关于 公司<202 ...

（二） 非经常性损益项目和金额 □适用 不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 □适用 不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为 经常性损益的项目的情形。 适用 □不适用 健帆生物科技集团股份有限公司 2023 年第一季度报告 四、季度财务报表 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|----------------------------------| | □ 是 否 | 本报告期 | 上年同期 | 本报告期比上年同期增减 （ % ） | | 营业收入（元） | 572,557,659.76 | 697,355,409.35 | -17.90% | | 归属于上市公司股东的净利润（元） | ...

Financial Performance - The company's total revenue for Q1 was approximately CNY 697.36 million, with a peak in Q2 at CNY 856.93 million, followed by a decline to CNY 471.42 million in Q3 and CNY 465.74 million in Q4[1]. - Net profit attributable to shareholders for Q1 was CNY 335.21 million, peaking in Q2 at CNY 412.95 million, but dropping significantly to CNY 16.09 million in Q4[1]. - The company's operating revenue for 2022 was ¥2,491,439,432.10, a decrease of 6.88% compared to the previous year[17]. - The net profit attributable to shareholders for 2022 was ¥889,537,704.85, reflecting a decline of 25.67% year-over-year[17]. - The net cash flow from operating activities for 2022 was ¥883,800,425.82, a decrease of 29.26% compared to 2021[17]. - In 2022, the company achieved a revenue of CNY 2.491 billion, a decrease of 6.88% year-on-year, and a net profit of CNY 890 million, down 25.67% year-on-year[28]. - The company reported a diluted earnings per share of CNY 1.1013 for the year[54]. - The company's total revenue for 2022 was approximately ¥2.49 billion, a decrease of 6.88% compared to ¥2.68 billion in 2021[135]. - The company reported a significant increase in blood purification equipment revenue, which rose by 163.18% to approximately ¥197.59 million[135]. - The gross profit margin for the medical device manufacturing sector was 82.70%, reflecting a decrease of 2.40% compared to the previous year[165]. Market Potential and Product Development - The market potential for blood perfusion treatment is estimated to exceed CNY 10 billion, with an annual market capacity of approximately 2.4 to 4 million devices based on 600,000 to 800,000 new cases of liver failure each year in China[8]. - The Double Plasma Molecular Adsorption System (DPMAS) is a new artificial liver treatment model that combines two products for enhanced blood purification, which has been included in several clinical guidelines[8]. - The company is actively participating in the "Voyage" project aimed at improving clinical practices in liver failure treatment through evidence-based training and standard operating procedures[13]. - The company is focusing on expanding its market through innovative treatment technologies and strategic partnerships in critical care areas[8]. - The company is actively exploring new product development, including DNA immunoadsorption columns and endotoxin adsorption columns, leveraging its advantages in ligand technology[28]. - The company aims to enhance its core competitiveness through the introduction of new products and technologies, including disposable blood/plasma adsorption products and continuous blood purification devices[180]. Research and Development - The company has initiated over 10 overseas clinical studies and published over 30 research papers in top international journals, promoting blood perfusion technology[14]. - The company's R&D investment reached ¥253.91 million, an increase of 46.12% year-on-year, accounting for 10.19% of total revenue[115]. - The company has a total of 306 authorized patents, including 59 invention patents, with 41 patents granted in 2022 alone[115]. - The company has conducted extensive training for over 100,000 medical staff nationwide, increasing awareness of its DPMAS artificial liver technology[125]. - The company's R&D team has grown to over 600 members, including 6 PhDs and more than 180 master's degree holders[115]. Sales and Market Expansion - The company has achieved product sales in 86 countries and has been included in the medical insurance directories of 11 countries, indicating successful market expansion[14]. - The company has established partnerships with regional core hospitals to create benchmark centers for blood purification technology and has published expert consensus on artificial liver devices[29]. - The company has expanded its renal product coverage to over 6,000 secondary and higher-level hospitals across China, focusing on chronic disease management and standardized treatment[92]. - The company has established a customer service center and a 24-hour hotline to enhance customer support and brand image[87]. - Jafron plans to expand its market presence in Southeast Asia, targeting a 30% growth in that region by 2024[39]. Operational Efficiency and Quality Control - The company has implemented automation in its main production processes and applied AI+ visual inspection technology to improve product quality[30]. - The company has established a quality management system since 2005, achieving ISO13485 certification and being recognized as a Class A medical device manufacturer in Guangdong Province for eleven consecutive years[89]. - The blood perfusion products are subject to strict quality control, with over 300 process documents and nearly 200 quality control documents in place[83]. - The company maintains a safety stock of approximately two months to meet market demand effectively[83]. Financial Management and Investments - The company has invested CNY 310 million in the Zhuhai Jian Shu New Materials Technology Co., Ltd. project, which focuses on automated production lines for raw material resins[30]. - The company has committed to donating to the "Artificial Liver Special Fund" for three consecutive years, supporting research in severe liver disease treatment[125]. - The company has faced challenges in international market sales, attributed to a significant decrease in critical illness patients and difficulties in promotional activities abroad[155].

证券代码：300529 证券简称：健帆生物 公告编号：2023-031 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于举办 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1 • 会议召开时间：2023 年 4 月 6 日（星期四）15:00-16:30 • 会议召开方式：网络互动方式 • 会议召开地点：价值在线（www.ir-online.cn） • 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 4 月 6 日 前 访 问 网 址 https://eseb.cn/13oYOLwIkik 或扫描下方小程序码，点击"进入会议"进行会 前提问，公司将通过本次业绩说明会上，在信息披露允许范围内就投资 者普遍关注的问题进行回答。 会议召开地点：价值在线（www.ir-online.cn） 健帆生物科技集团股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日 在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便 于广大投资者更加 ...

证券代码：300529 证券简称：健帆生物 珠海健帆生物科技股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |------------------------|-------------------------------|---------------------------------------| | | | | | 投资者关系活动类别 | ■ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 富国基金 姜恩铸 | | | | 泰康资产 王晓峰 | | | | 大成基金 陈丹霞 | | | | 汇添富 付鹏飞 | | | | 申万宏源 孙辰阳、熊超逸 | | | | 汇利资产 叶丽 | | | | 兴业证券 张佳博 | | | | 兴业全球基金 张弘 | | | | 上善若水资管 叶晓珊 | | | | 兰权资本 薛康、李龙辉、詹晓文 | | | | 前海联合 彭波 | ...

证券代码：300529 证券简称：健帆生物 编号：2017-001 珠海健帆生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------|------------------------------|--------------------------------------| | | | | | 投资者关系活动类别 | ■ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓 | 平安证券 倪亦道 | | | 名 | | 广东民营投资股份有限公司 吕金平 | | 时间 | 2017 年 3 月 3 日 | 14:00-16:00 | | 地点 | 公司研发大楼 | | | 上市公司接待人员姓名 | 总经理助理：李峰 | | | 投资者关系活动主要内 | 一、参观公司 | | | 容介绍 | 二、介绍公司基本情况 | | | | 三、沟通交流会。具体如下： | | | ...